SCHEMBL6316490

SCHEMBL6316490

CCCCCCCNC(=O)c1c(-c2ccc(CC)s2)noc1N

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 4/20 0.43
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
CA2 P00918 2/20 0.41
CA1 P00915 1/20 0.41
CA4 P22748 1/20 0.41
CA7 P43166 1/20 0.41
NAAA Q02083 3/20 0.41
GAA P10253 1/20 0.40
TP53 P04637 1/20 0.40
MDM2 Q00987 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
HPGD P15428 1/20 0.39
HDAC6 Q9UBN7 4/20 0.39
HDAC1 Q13547 2/20 0.39
HDAC3 O15379 2/20 0.39
NCOR2 Q9Y618 2/20 0.39
HDAC4 P56524 1/20 0.39
HDAC2 Q92769 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6321721 1.00 ALOX15 (0.43) ALOX15ALDH1A1LMNASMN1; SMN2CA2
SCHEMBL6317695 1.00 ALOX15 (0.43) ALOX15ALDH1A1LMNASMN1; SMN2CA2
SCHEMBL6315932 0.99 ALOX15 (0.42) ALOX15ALDH1A1LMNASMN1; SMN2CA2
SCHEMBL6317722 0.96 CA1 (0.42) ALOX15LMNASMN1; SMN2CA2CA1
SCHEMBL6322769 0.90 ALOX15 (0.43) ALOX15ALDH1A1LMNASMN1; SMN2CA2
SCHEMBL6319057 0.90 ALOX15 (0.43) ALOX15ALDH1A1LMNASMN1; SMN2CA2
SCHEMBL6324330 0.90 ALOX15 (0.43) ALOX15ALDH1A1LMNASMN1; SMN2CA2
SCHEMBL6318885 0.90 ACKR3 (0.41) ALDH1A1LMNASMN1; SMN2CA2CA1
SCHEMBL6321826 0.89 GAA (0.43) ALOX15ALDH1A1LMNASMN1; SMN2CA2
SCHEMBL6314783 0.88 CA1 (0.54) ALOX15ALDH1A1LMNASMN1; SMN2CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 ALOX15 2753/4885ALDH1A1 4444/4885LMNA 3334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.